






































 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Intraoperative Goal-directed Fluid Therapy in Elective
Major Abdominal Surgery
A Meta-analysis of Randomized Controlled Trials
Katie E. Rollins, MRCS and Dileep N. Lobo, DM, FRCS, FACS, FRCPE
Objectives: To compare the effects of intraoperative goal-directed fluid
therapy (GDFT) with conventional fluid therapy, and determine whether
there was a difference in outcome between studies that did and did not use
Enhanced Recovery After Surgery (ERAS) protocols.
Methods: Meta-analysis of randomized controlled trials of adult patients
undergoing elective major abdominal surgery comparing intraoperative
GDFT versus conventional fluid therapy. The outcome measures were post-
operative morbidity, length of stay, gastrointestinal function and 30-day
mortality.
Results: A total of 23 studies were included with 2099 patients: 1040 who
underwent GDFT and 1059 who received conventional fluid therapy. GDFT
was associated with a significant reduction in morbidity (risk ratio [RR] 0.76,
95% confidence interval [CI] 0.66–0.89, P¼ 0.0007), hospital length of stay
(LOS; mean difference 1.55 days, 95% CI 2.73 to 0.36, P¼ 0.01),
intensive care LOS (mean difference 0.63 days, 95% CI 1.18 to 0.09,
P¼ 0.02), and time to passage of feces (mean difference 0.90 days, 95% CI
1.48 to 0.32 days, P¼ 0.002). However, no difference was seen in
mortality, return of flatus, or risk of paralytic ileus. If patients were managed
in an ERAS pathway, the only significant reductions were in intensive care
LOS (mean difference 0.63 days, 95% CI 0.94 to 0.32, P< 0.0001) and
time to passage of feces (mean difference 1.09 days, 95% CI 2.03 to
0.15, P¼ 0.02). If managed in a traditional care setting, a significant
reduction was seen in both overall morbidity (RR 0.69, 95% CI 0.57 to
0.84, P¼ 0.0002) and total hospital LOS (mean difference 2.14, 95% CI
4.15 to 0.13, P¼ 0.04).
Conclusions: GDFT may not be of benefit to all elective patients undergoing
major abdominal surgery, particularly those managed in an ERAS setting.
Keywords: complications, goal-directed fluid therapy, intraoperative, meta-
analysis, outcome
(Ann Surg 2016;263:465–476)
I ntraoperative hypovolemia caused by loss of as little as 10% to15% of blood volume can result in an appreciable fall in splanch-
nic perfusion, which often outlasts the period of hypovolemia.1 This
results in an intramucosal acidosis of the gut,2 leading to a cascade of
events that impair postoperative gastrointestinal function and cause
complications. 3 Postoperative gastrointestinal morbidity in the form
of an inability to tolerate oral or enteral tube feeding, nausea,
vomiting, and abdominal distension can be responsible for over half
of delayed discharges.4 This concept led to the use of intraoperative
goal-directed fluid therapy (GDFT) in which relatively small-volume
(200–250 mL) boluses of fluid (usually a colloid) over background
crystalloid infusions have been used to increase stroke volume and
cardiac output, improve gut perfusion,1 and decrease gut mucosal
acidosis.
A number of methods, including transesophageal Doppler
(TED), lithium dilution, arterial pulse contour analysis, thoracic
electrical bioimpedance, partial non-rebreathing systems, and trans-
pulmonary thermodilution techniques have been used to measure
intraoperative stroke volume and cardiac output and, thereby, help
direct fluid therapy.5 The methods used most frequently in clinical
practice are the TED and lithium dilution techniques. The commonest
algorithm assesses the change in stroke volume in response to a fluid
bolus of 200 to 250 mL infused over 5 to 10 minutes. An increase in
stroke volume of more than 10% in response to this bolus signifies
hypovolemia and indicates the need for a further bolus. An increase in
stroke volume of 10% or less suggests adequate filling and continu-
ation of the background crystalloid infusion without the need for
another fluid bolus. A reduction in stroke volume by more than 10%
during continued monitoring necessitates a further bolus and repetition
of the cycle. Variations in this methodology include monitoring of
stroke volume variation and corrected flow time (FTc).6,7
Randomized controlled trials and meta-analyses8–11 pub-
lished in the first decade of the twenty-first century suggested that
intraoperative GDFT resulted in a statistically significant reduction
in postoperative complication rates and length of stay (LOS) when
compared with patients receiving conventional intraoperative fluid
therapy. This led to intraoperative GDFT being recommended as a
standard of care by the UK National Institute for Health and Clinical
Excellence (NICE).12 However, postoperative fluid therapy regimens
were not clear in most of the early studies, and perioperative care was
not standardized. Avoidance of postoperative salt and water overload
and maintaining patients in as near a state to zero fluid balance as
possible has been shown to reduce both complication rates and length
of hospital stay even in patients not receiving GDFT.13–16 In
addition, the use of fast-track or Enhanced Recovery After Surgery
(ERAS) protocols,17,18 which are multimodal perioperative care
pathways designed to reduce the metabolic stress of surgery and
accelerate postoperative recovery, have resulted in fewer compli-
cations [risk ratio 0.5, 95% confidence interval (CI) 0.4–0.7] and
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reduction in LOS by 2.5 (95% CI3.5 to1.5) days after colorectal
surgery when compared with patients managed with traditional
care.19 More recent trials14,17,18 in which patients have been managed
within ERAS protocols with avoidance of postoperative fluid over-
load have suggested that, although intraoperative GDFT resulted in
improvement of cardiovascular variables when compared with con-
ventional fluid therapy, there was no significant difference in clinical
outcomes.14,20,21
The aims of this meta-analysis of randomized clinical trials of
intraoperative GDFT versus conventional fluid therapy in patients
undergoing elective major abdominal surgery were to
 compare the effects of intraoperative GDFT with conventional
fluid therapy on postoperative complications, length of hospital
stay, gastrointestinal function, and mortality.
 determine whether there was a difference in outcome between




A search of the PubMed, MEDLINE, Web of Science,
GoogleTM Scholar, and Cochrane Library databases was con-
ducted to identify studies evaluating the impact of intraoperative
goal-directed fluid therapy on postoperative elective surgical out-
comes in all branches of surgery published in all languages
between January 1995 and December 2014. Electronic search
terms used were [‘‘goal-directed fluid therapy’’ OR ‘‘flow-
directed fluid therapy’’] AND [‘‘surgery’’ OR ‘‘intraoperative’’]
and the search was limited to adult patients undergoing elective
surgery. The bibliography of studies that met the inclusion criteria
were also searched for other relevant articles and conference
abstracts to ensure study inclusion was as comprehensive as
possible. The meta-analysis was conducted according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement.22
Selection of Articles
Full-text articles were screened after exclusion of citations on
the basis of article title and abstract. We selected studies if they
included adult patients undergoing elective major abdominal surgery
who were randomized to receive either GDFT or conventional intra-
operative fluid therapy and if the study reported at least 1 relevant
postoperative outcome. ‘‘Major abdominal surgery’’ included general,
vascular, gynecologic, and urologic procedures where the bowel was
handled. We excluded studies if they involved patients undergoing
non-abdominal surgery such as cardiac, orthopedic, or peripheral
vascular surgery, included emergency surgical procedures, did not
report any relevant clinical outcome measures, or if both groups
received GDFT. One study23 was excluded due to retraction of a large
number of articles by 1 of the authors. We discussed studies where the
inclusion criteria were not clear and made a final decision.
Data Extraction
Data were extracted by 1 author (KER) and checked by
another (DNL). The primary outcome measure was postoperative
morbidity with secondary outcome measures being 30-day mortality,
hospital and intensive care LOS, time to return of gastrointestinal
function (flatus and feces), and incidence of paralytic ileus. Data
were also collated on patient demographics (age, sex, American
Society of Anesthesiology [ASA] grade), surgical variables (surgical
procedure, number of laparoscopic cases, and estimated blood loss),
and intraoperative fluid administration (overall, colloid and
crystalloid, and inotrope administration). We noted the method of
administration of GDFT and whether patients were managed
using ERAS principles (eg, if stated by the authors or having a
combination of 4 or more elements such as avoidance of prolonged
preoperative starvation, provision of preoperative carbohydrate load-
ing, use of thoracic epidural analgesia, avoidance of premedication,
opioids and postoperative fluid overload, and early postoperative
feeding and mobilization)17,18 or traditional care. We contacted the
corresponding author on 3 occasions over a 6-week period if the data
required were not available in the article. If the authors did not
provide the data, the medians and interquartile ranges (IQR) were
converted to means and standard deviations (SDs) using the tech-
nique described by Hozo et al.24 This technique uses the median as
the best estimate of the mean, and the SD is calculated by the
following formula:
SD ¼ Upper limit of IQR Lower limit of IQR
1:35
The risk of bias was assessed using the Cochrane Collabor-
ation tool in RevMan 5.3,25 which focuses upon random sequence
generation (selection bias), allocation concealment (selection bias),
blinding of participants and personnel (performance bias), blinding
of outcome assessment (detection bias), incomplete outcome data
(attrition bias), and selective reporting (reporting bias).
Statistical Analysis
RevMan 5.3 software25 was used for data analysis. Dichoto-
mous variables were quoted as a risk ratio (RR) with 95% CI and
analyzed using the Mantel–Haenszel random effects model. Continu-
ous variables were quoted as a mean difference using a random effects
model with 95% CI and analyzed using the inverse-variance random
effects model. Forest plots were constructed and a P value less than
0.05 on 2-tailed testing signified a statistically significant difference.
Study heterogeneity and inconsistency was assessed using the I2
statistic26: less than 25%—low heterogeneity, 25% to 50%—moderate
heterogeneity, and more than 50%—high heterogeneity. A predeter-
mined secondary analysis was conducted on results obtained when the
intervention was delivered within or without ERAS protocols. The
quality of the evidence for each outcome was comprehensively
assessed and graded using GRADEpro software.27
Protocol Registration




From 294 studies identified, 23 studies were eligible for inclu-
sion (Fig. 1).6,7,21,28–47 There were 8 studies based in colorectal sur-
gery,6,21,36–39,45,46 1 in upper gastrointestinal surgery,29 2 in urology,34,40
1 in abdominal vascular surgery,47 1 in gynecology,35 and 10 in
a range of abdominal procedures.7,28,30–33,41–44 The risk of bias in
the studies included was low and, in general, study quality was high (see
Supplemental Digital Content Table 1, available at http://links.lww.com/
SLA/A853). The quality of the evidence for each outcome in the meta-
analysis is summarized in Supplemental Digital Content Table 2,
available at http://links.lww.com/SLA/A854. Although there was no
risk of bias or indirectness for all end-points, therewas inconsistency and
imprecision for hospital and intensive therapy unit (ITU) LOS.
Demographics
The 23 randomized controlled trials included a total of 2099
patients, of whom 1040 had been randomized to intraoperative
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GDFT and 1059 to traditional intraoperative fluid management
strategies. GDFT was administered as part of an ERAS program
in 10 studies6,21,30,34,36–40,45 and as part of a traditional recovery
pathway in 13.7,28,29,31–33,35,41–44,46,47 The method for administering
GDFT in the studies was: TED in 12,6,7,21,34–40,45,46 hemodynamic
parameters from radial arterial line (including lithium dilution) in
9,29–33,42–44,47 pleth variability index from the pulse oximeter in 1,41
and a noninvasive cardiac output monitoring device in 1.28 Patient
demographics are detailed in Table 1.
Fluid Therapy
There was some variation in fluid therapy over time (Table 2).
One of the earliest studies7 infused 4405 2650 mL lactated Ringer
solution and 847 373 mL 6% hydroxyethyl starch (HES) intra-
operatively in the GDFT group versus 4375 2452 mL Ringer and
282 470 mL HES in the control group. In contrast, the most
recently published study21 administered 1500 mL (1000–
2000 mL) intraoperative crystalloid and 500 mL (250–750 mL)
colloid in the GDFT group versus 1400 mL (1000–1900 mL) and
0 mL (0–300 mL) in the control group.
Morbidity
Eighteen studies6,7,21,28,31,32,35–39,41,42,44–47 on 899 patients
managed with GDFT versus 914 patients with traditional fluid
management reported morbidity rates (Fig. 2). These were further
divided by whether the patients had been managed as part of an
ERAS pathway (866 patients) or as part of a traditional care pathway
(947 patients). One study30 focused on cardiac morbidity alone, but
these data are included in the overall analysis. Overall morbidity
was significantly lower in patients managed with GDFT versus
those in the control group (RR 0.76, 95% CI 0.66–0.89,
P¼ 0.0007). When just those managed with GDFT in a traditional
care pathway setting were considered, morbidity rates were also
significantly lower in the GDFT group when compared with controls
(RR 0.69, 95% CI 0.57–0.84, P¼ 0.0002). However, when the
GDFT was administered in conjunction with an ERAS pathway,
it did not result in a reduction in morbidity risk (RR 0.86, 95% CI
0.70–1.05, P¼ 0.14). The funnel plot for the primary outcome
measure of morbidity showed no major asymmetry to indicate a
significant bias in either group.
Mortality
Mortality rates were detailed in 18 studies6,7,21,28,29,32,35,37–47
that included 855 patients in the GDFT group and 870 in the
traditional group (Fig. 3). Overall, there was no statistically signifi-
cant difference in the incidence of mortality between GDFT and
control patients, nor was there any difference in those managed with
an ERAS pathway or traditional care.
Hospital Length of Stay
Overall hospital LOS was reported in all studies except one32
included in the meta-analysis (Fig. 4). However, 2 studies30,34
reported only median (IQR) data, and we were unable to obtain
the meanSD from the authors. These data were estimated using the
technique described by Hozo et al.24 and all data were included in the
analysis of hospital LOS. There were 1043 patients managed in an
ERAS setting and 1014 in a traditional setting (Fig. 4). GDFT
resulted in a significant decrease in hospital length of stay in the
overall group (mean difference1.55 days, 95% CI2.73 to0.36,
P¼ 0.01). If patients managed in a traditional care setting were
specifically examined, GDFT again resulted in a significant
reduction in overall hospital LOS (mean difference 2.14 days,
95% CI 4.15 to 0.13, P¼ 0.04). However, there was no signifi-
cant difference in hospital LOS in those managed with an ERAS
pathway (mean difference 0.71 days, 95% CI 1.91 to 0.49,
P¼ 0.25).
Intensive Care Length of Stay
Postoperative LOS in the ITU was reported in 8 stud-
ies28,30,32,41–44,46 (Fig. 4). Again, 3 studies30,44,46 provided only median
(IQR) data; therefore, estimated meanSD data were included for
these studies. Only 1 study in an ERAS setting reported intensive care
LOS,30 whereas 7 studies in a traditional setting reported this. GDFT
resulted in a significant reduction in intensive care LOS (Fig. 4) in all
patients (mean difference 0.63 days, 95% CI 1.18 to 0.09,
P¼ 0.02) and in the 1 study in which patients were managed with
an ERAS pathway (mean difference 0.63 days, 95% CI 0.94 to
0.32, P< 0.0001). GDFT, however, made no significant difference to
intensive care LOS in those patients managed within a traditional
care setting.
Return of Gastrointestinal Function
Eleven studies examined time to return of gastrointestinal
function postoperatively, in the form of passage of flatus,28,31,38
feces,6,29,33,35,45 or both.30,39,40 First, considering time to passage flatus
in all studies including those with calculated data (Fig. 5), there were
334 patients who were managed with GDFT and 345 in the control
group. There was no significant difference in the time to passage of
flatus in either the overall group or in those managed in combination
with traditional care or an ERAS pathway.
When time to passage of feces was considered, 365 patients
were managed with GDFT and 370 with control intraoperative fluid
(Fig. 5). GDFT resulted in a significant reduction in time to passage
of feces in the overall group (mean difference 0.90 days, 95%
CI 1.48 to 0.32 days, P¼ 0.002) as well as those managed with
GDFT in combination with an ERAS pathway (mean difference
1.09 days, 95% CI 2.03 to 0.15, P¼ 0.02). However, this
difference was not significant in patients managed in a traditional
care setting.
Incidence of Postoperative Ileus
Seven studies (707 patients) included data on the incidence of
postoperative ileus in 345 patients managed with intraoperative
FIGURE 1. PRISMA diagram showing identification of relevant
studies from initial search.
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GDFT versus 362 patients in the control group6,21,28,36–38,40 (Fig. 5).
The use of GDFT did not affect the incidence of postoperative ileus
significantly in either the overall group or in those managed in
combination with either traditional care or an ERAS pathway.
DISCUSSION
This meta-analysis of 23 randomized controlled trials including
2099 patients has demonstrated that, in patients undergoing elective
major abdominal surgery, GDFT was associated with a significant
reduction in overall morbidity, LOS (both hospital and intensive care),
and time to passage of feces when compared with conventional
intraoperative fluid therapy when all studies were considered. How-
ever, there were no significant differences in short-term mortality, time
to passage of flatus, or risk of paralytic ileus.
When the effect of GDFT was considered in the setting of
ERAS pathways, which are being implemented increasingly interna-
tionally, there was no statistically significant impact on morbidity
and mortality, hospital LOS, time to passage of flatus, or incidence of
paralytic ileus. A significant reduction in intensive care LOS with
GDFT was seen, but this was based on a single study.30 When the
impact of GDFT was considered in the setting of a traditional care
pathway, a significant reduction in morbidity and overall hospital
LOS was seen when compared with controls, but there was no
significant difference in any other outcome considered.
The studies included in this meta-analysis were conducted
over a 12-year period during which significant advances have been
made in the concept and implementation of ERAS principles and
there is evidence that ERAS programs are associated with reduced
hospital LOS,19,48,49 decreased morbidity, and improved cost-effec-
tiveness.50 The studies were conducted in a variety of surgical special-
ties which have differing expected LOS; however, if the studies
examining colorectal surgery alone are analyzed,6,21,36–39,45 LOS
has declined progressively over a temporal scale from 12.0 7.5 days
in 2005 45 to 7.48 3.8 days in 2014.21 With the ongoing push for
decreasing LOS, reinforced by recent reports of 2-day51 and 23-hour52
hospital stays for laparoscopic colorectal resection, the margin for
overall improvement in LOS provided by GDFT may decrease.
Overall heterogeneity was high for LOS (90%) and, although it
reduced to 61% for the ERAS group, it was still high. Therefore, it
is not certain whether the lack of difference in the LOS in the ERAS
subgroup was a time-dependent effect or a reflection of the effect of
ERAS pathways.
The other issue raised by the temporal spread of the results is
that of the volume of fluid infused intraoperatively. This volume has
changed drastically from the earliest to more recent papers, with a
progressively greater difference in volume infused between GDFT
and conventional fluid management groups, suggesting that the
concept and impact of GDFT may have changed during this period.
It is possible that, in the early phase of introduction of GDFT, patients
were being frequently fluid overloaded intraoperatively. Given that
postoperative morbidity is associated in a U-shaped manner with the
volume of intraoperative fluid infused,51 excessive fluid adminis-
tration in some of these studies may have attenuated some of the
potential benefits of GDFT. Further to this, the majority of early
studies did not consider the importance of postoperative salt and
water overload, which may also have impacted negatively on out-
come. In contrast, near-zero fluid balance is considered more care-
fully in recent studies due to advancing knowledge of the importance
of these factors52 in the perioperative setting. The provision of high–
chloride-containing fluids, with the resultant undesirable hyper-
chloremic acidosis,53–55 may also have masked some benefits pro-
vided by GDFT. Worldwide, there is now a move away from 0.9%
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may lead to a further improvement in outcomes.56 One further factor
to consider is that different studies have employed different goals for
GDFT, and the emphasis of this has evolved over time. In the earlier
studies included in this meta-analysis, patients were given fluid
boluses if they were fluid responsive, regardless of their hemody-
namic status, to maximize stroke volume by pushing patients to the
top of their Frank–Starling curve. This approach is likely to result in
fluid overload by ‘‘optimizing’’ patients to a point where they are no
longer fluid responsive rather than assessing ‘‘good enough’’ resus-
citation. In contrast, more contemporary studies administer bolus
fluid only if patients were fluid responsive and had evidence of
hemodynamic compromise, which may be reflected in the overall
smaller volumes administered in more recent studies where a target
of near-zero fluid balance was employed.
FIGURE 2. Forest plot comparing overall
morbidity rate for patients receiving
GDFT versus control, divided by those
managed using ERAS or traditional prin-
ciples. A Mantel–Haenszel random
effects model was used to conduct the
meta-analysis, and risk ratios are quoted
including 95% confidence intervals.
(Zheng et al., 201330 considered cardiac
morbidity alone).
FIGURE 3. Forest plot comparing in-hos-
pital or 30-day mortality rate for patients
receiving GDFT versus control, divided by
those managed using ERAS or traditional
principles. A Mantel–Haenszel random
effects model was used to conduct the
meta-analysis, and risk ratios are quoted
including 95% confidence intervals.
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The present study was conducted using rigorous method-
ology and represents the largest meta-analysis examining the role of
GDFT versus conventional intraoperative fluid management in
patients undergoing elective major abdominal surgery. Not only
did we set out to establish the difference in clinical outcome
measures but also at the outset a secondary outcome of comparing
those managed within ERAS pathways with those who were man-
aged in traditional care setting was specified. This secondary
analysis has resulted in some interesting observations in outcomes
between the 2 settings, which appear to differ considerably. A
further strength was that to ensure the data were as complete as
possible for all studies included, most importantly the meanSD
data for continuous variables, all authors were contacted on 3
separate occasions requesting the necessary raw data rather than
the median (IQR). Unfortunately, not all authors responded to the
request for information, and data for several studies 30,34,40,44 were
estimated for inclusion in the meta-analysis. This estimation was
done using an established method24 that has been employed in other
meta-analyses.
This meta-analysis had several weaknesses inherent in its
design and conduct. The methodology for conducting GDFT
differed greatly between studies, including TED,6,7,21,34–40,45,46
hemodynamic parameters from an arterial line,29–33,42–44,47 pleth
variability index from the pulse oximeter,41 and a noninvasive
cardiac output monitoring device.28 Inclusion of all techniques
for conducting GDFT was chosen purposefully to ensure that the
conclusions of this meta-analysis were generalizable to different
GDFT methods. However, subgroup analyses comparing the various
methods was not feasible because of the small numbers of patients
who were managed with techniques other than TED or monitoring of
hemodynamic parameters from arterial lines. One factor that was
not measured consistently between the studies was that of post-
operative fluid administration and overall balance, which may
significantly impact upon some of the postoperative outcomes.
The use of rescue therapy such as diuretics and inotropes is also
difficult to discern from the studies. None of the ERAS pathway
studies included an assessment of compliance with the ERAS
standards, which is particularly important because of the correlation
between compliance with the standards and clinical outcomes.57–59
There was a large degree of heterogeneity in the studies
included in this review. Using the I2 statistic26 for the 7 clinical
outcomes, 1 outcome had low (I2< 25%), 3 had moderate (I2 25%–
50%), and 3 had high heterogeneity (I2> 50%). This great variation
may have impacted upon the significance of the results. In addition,
FIGURE 4. Forest plot comparing overall
hospital LOS (top) and intensive treat-
ment unit (ITU) LOS (bottom) for
patients receiving GDFT versus control
including studies with estimated data,
divided by those managed using ERAS
or traditional principles. An inverse-var-
iance random effects model was used to
conduct the meta-analysis, and mean
differences are quoted including 95%
confidence intervals.
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to improve generalizability, we included all studies that included
patients who had major abdominal surgery where the bowel was
handled. It was also not possible to differentiate the effects of
temporal changes in perioperative management algorithms and other
treatment interventions such as the use of vasopressors from the
effect of GDFT.
NICE guidance12 released in 2011 on the use of TED-guided
fluid therapy has recommended its use ‘‘in patients undergoing major
or high-risk surgery or other surgical patients in whom a clinician
would consider using invasive cardiovascular monitoring.’’ However,
this guidance was made mainly on the findings of older studies, some
of which were on patients undergoing cardiac and hip fracture
surgery and most of which were conducted within a traditional
setting of perioperative care. All studies included in the present
meta-analysis focused on patients who would meet the criteria for
major or high-risk surgery, making this meta-analysis an excellent
setting in which to examine the potential benefits of this technique.
By comparing the older studies with newer studies that have been
conducted using multimodal enhanced recovery perioperative care
pathways, we have shown in our meta-analysis that modern peri-
operative care reduces the impact of GDFT on outcome. This could
help inform healthcare providers better and facilitate a more rational
FIGURE 5. Forest plot comparing time to
return of flatus and feces and incidence of
paralytic ileus for patients receiving GDFT
versus control including studies with esti-
mated data, divided by those managed
using ERAS or traditional principles. An
inverse-variance random effects model
was used to conduct the meta-analysis,
and mean differences are quoted includ-
ing 95% confidence intervals. The Man-
tel-Haenszel random effects model with
risk ratios was used for postoperative
ileus.
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decision-making process before recommending GDFT as ‘‘standard
of care.’’ Given the unclear benefits of GDFT found in this study,
particularly in those managed within an ERAS pathway, it is
uncertain whether this recommendation ought to be adopted for
all patients undergoing elective major abdominal surgery.
The bolus fluid administered as part of the GDFT protocol in the
included studies was variable, with HES being the documented fluid
administered in 14 studies.7,21,28,29,32,34,35,37,39,41–44,46 However, there
has recently been a moratorium in Europe on the use of HES due to
concerns of increased risk of acute kidney injury requiring renal re-
placement therapy,60–62 as well as mortality60,62 based on recent
randomized controlled trials in critically ill patients. Given that much
of the evidence in this study, as well as other meta-analyses, are based
upon the use of HES as the bolus fluid administered for GDFT, the
impact of GDFT using gelatin (or other colloid)-based fluid may differ
from current evidence. Further literature63 has examined the role of
balanced crystalloid (Hartmann solution) versus colloid (6% HES) as
the bolus agent for GDFT, demonstrating no clinical benefit from
colloid in terms of morbidity or coagulopathy. Only 2 of the studies
included in this meta-analysis30,47 administered crystalloid as the bolus
agent. Crystalloids may be increasingly utilized in future studies
regarding GDFT due to suggested therapeutic equivalence of colloid
and crystalloid in combination with concerns with regard to some
forms of colloid.
An updated meta-analysis on perioperative administration of
fluids, with or without inotropes/vasoactive drugs, targeted to increase
blood flow (relative to control) against measured goals in patients
undergoing abdominal and extra-abdominal surgery, including emer-
gency procedures showed that patients randomized to a hemodynamic
therapy algorithm, had fewer complications and shorter LOS than
controls.64 Nevertheless, the findings of the present meta-analysis for
patients managed within ERAS pathways are in agreement with a
previous meta-analysis of 6 trials of 691 patients undergoing elective
colorectal surgery in which it was shown that TED-guided GDFT did
not influence LOS or complications.65
However, although the benefits of GDFT on clinical outcomes
may be marginal, the presence of an important benefit such as cost
savings cannot be ruled out on the basis of this meta-analysis. Further
large-scale randomized trials addressing all the issues that we have
highlighted, including a cost-effectiveness analysis, are necessary
before the real impact of GDFT in elective abdominal surgery is known.
CONCLUSIONS
This meta-analysis has shown that the benefits of GDFT may
not be as clear as has been suggested historically. The overall peri-
operative management of patients has changed during the period of
inclusion of studies in this meta-analysis, including decreasing
expected hospital LOS, overall decreasing volumes of intraoperative
fluid infusion, avoidance of postoperative salt and water overload, and
introduction and compliance with ERAS programs. Despite the NICE
Guidance12 which recommends that GDFT technology should be used
‘‘in patients undergoing major or high-risk surgery,’’ this study
suggests that GDFT may not be of use to all elective patients under-
going major abdominal surgery. The benefit conveyed by GDFT is
particularly attenuated by its combination with ERAS pathways that
are being increasingly implemented internationally. GDFT may be
more of use in the intraoperative care of high-risk patients; however, as
yet, there are no definitive data to support this belief.
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